Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Thalia Therapeutics PLC

THAT.L ✓ COMPLIANT ☆ Track — members

LSE · Healthcare · Biotechnology & Medical Research ·

UK Micro Cap Analyst: N/A

Last Close

$0.01

▲ +0.00%

Market Cap $15.74M · Vol 168.22K

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$15.74M

Micro Cap

Div Yield

N/A

Annual dividend

EPS Growth

N/A

YoY

RSI (14)

0.00

Momentum

Beta

1.95

vs Market

52W High

$0.01

34.43% below

52W Low

$0.01

67.98% above

Volume

168.22K

Avg 1.05M

P/B

4.08

Price-to-book

ROE

N/A

Return on equity

Free Float

41.35%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Thalia Therapeutics PLC (THAT.L) stock is Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does THAT.L pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+0.00%

-7.14%

+0.00%

+18.18%

YTD

+23.81%

+30.00%

-53.04%

-92.78%

Financials & Valuation

TTM · Annual

Total Revenue	$9.78K
Net Income	$-1,627,811.00
Revenue Growth (YoY)	+5.86%
Gross Margin	100.00%
Operating Margin	-16,041.04%
Net Profit Margin	-16,632.90%
ROE	N/A
ROA · ROIC	-119.86% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	523.56
P/B	4.08
P/FCF	N/A
EPS Growth	N/A
Outstanding Shares	1.78B

Technical Indicators

50-Day SMA	$0.01
200-Day SMA	$0.01
RSI (14)	0.00
Beta	1.95
52-Week High	$0.01
52-Week Low	$0.01

Volume Today	168.22K
Avg Daily Volume (30D)	1.05M
Relative Volume	0.16x
Volatility (10D)	17.90
Volatility (30D)	26.20
Free Float	41.35%

Analyst Consensus

N/A

Current Price $0.01

Mean Target N/A

52W Low$0.01 52W High$0.01

Current

Target

$0.01 $0.01

Current Analyst target

· 0 analysts

Identifiers

ExchangeLSE

FIGIBBG001SBT9Q3

ISINGB00BYW8QM32

CountryUnited Kingdom

Sub-IndustryBio Therapeutic Drugs

Earnings DateN/A

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

2359.HK WuXi AppTec Co Ltd -3.94% ARGX.BR argenx SE -4.19% ARGX argenx SE -2.76% INSM Insmed Inc -1.42% 2269.HK WuXi Biologics (Cayman) Inc -4.71%

Company Profile

Thalia Therapeutics PLC, formerly N4 Pharma plc, is a biotechnology company developing RNA-based therapeutics and delivery technologies in oncology and cardiovascular disease. The Company is developing proprietary RNA delivery technologies (Nuvec) designed to enable multi-RNA loading, flexible targeting and the potential for oral delivery. Nuvec is based on amorphous silica and has an irregular surface structure that simply and effectively traps and protects RNA as it travels to target cells. The Nuvec delivery system can be functionalized by attaching a wide range of proteins, peptides, antibodies or radionuclides for therapeutic purposes. The Company has a growing pipeline of RNA-based programs across oncology and cardiovascular disease, including Dual-target cardiovascular siRNA program and Proprietary RNA delivery technology. The Company is advancing a novel long-duration, dual-acting siRNA program targeting PCSK9 and lipoprotein.